It is formulated by 15 pharmaceutical companies such as TEVA PHARMS, AUROBINDO PHARMA, CHARTWELL RX and others. It is marketed under 1 brand name, including VALACYCLOVIR HYDROCHLORIDE. Available in 2 different strengths, such as EQ 1GM BASE, EQ 500MG BASE, and administered through 1 route including TABLET;ORAL.
Global Patent Coverage & Expiry Overview
Track protection status across key markets to assess launch feasibility.
Strategic Dashboard
info
insightsStrategic Insights
Sourcing & Feasibility
check_circleAPI availability:autorenew
Loading API feasibility...
NDA (New Drug Application)
ANDA (Generic Application)
US Orange Book Patents Expiration Timeline
Key expiration dates for US patents covering this ingredient
Orange Book Drug Strengths
Latest drug strengths approved by FDA
Strength
Route of Administration
Companies
Latest Approval Date
Orange Book Patents
Patents approved by the FDA for the ingredient
📄
No US Orange Book patents found
Recent Clinical Trials
Latest clinical trials and research studies for this ingredient
NCT ID
Title
Status
Phase
Conditions
Start Date
Completion Date
API Suppliers/Manufacturer (Branded/Generic companies)
Manufacturing Locations
APOTEX
Total Dosages: 2
Manufacturing Locations: 10
AUROBINDO PHARMA
Total Dosages: 2
Manufacturing Locations: 5
CHARTWELL RX
Total Dosages: 2
CIPLA
Total Dosages: 2
Manufacturing Locations: 7
GRAVITI PHARMS
Total Dosages: 2
HETERO LABS LTD V
Total Dosages: 2
HIKMA
Total Dosages: 2
Manufacturing Locations: 6
JUBILANT GENERICS
Total Dosages: 2
Manufacturing Locations: 1
MYLAN PHARMS INC
Total Dosages: 2
NORVIUM BIOSCIENCE
Total Dosages: 2
SANDOZ
Total Dosages: 2
Manufacturing Locations: 9
SUN PHARM INDS LTD
Total Dosages: 2
TEVA PHARMS
Total Dosages: 2
WATSON LABS INC
Total Dosages: 2
YILING
Total Dosages: 2
Manufacturing Locations: 3
ZYDUS LIFESCIENCES
Total Dosages: 2
Manufacturing Locations: 13
Supplier Details
Dosages
Supplier Locations
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.